IMPACT Therapeutics' Senaparib Capsules Receive NMPA Approval for Maintenance Treatment of Advanced Ovarian Cancer in China

 IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on s...

January 20, 2025 | Monday | News
Fermion and Simcere Partner to Advance Innovative SSTR4 Agonist for Pain Management in Greater China

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited (HKEX: 2096) have announced a partnership to develop a clinical-stage pain ...

January 20, 2025 | Monday | News
Innovent Biologics’ IBI343 Receives Breakthrough Therapy Designation for Advanced Pancreatic Cancer in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

January 16, 2025 | Thursday | News
AbbVie and Simcere Zaiming Partner to Develop SIM0500 for Relapsed/Refractory Multiple Myeloma

NORTH CHICAGO, Ill. and SHANGHAI, AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) ann...

January 14, 2025 | Tuesday | News
China Approves Sarclisa for Relapsed/Refractory Multiple Myeloma, Expanding Treatment Options

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethaso...

January 14, 2025 | Tuesday | News
Vertex Pharmaceuticals and Zai Lab Announce Exclusive Collaboration for Development and Commercialization of Povetacicept in Asia

-Vertex Pharmaceuticals Incorporated  and Zai Lab Limited announced an exclusive collaboration and license agreement for the development a...

January 13, 2025 | Monday | News
Windward Bio Launches with $200M Series A Financing to Develop Breakthrough Immunology Treatments

Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...

January 12, 2025 | Sunday | News
Zai Lab and MediLink Forge Global Partnership to Develop Groundbreaking LRRC15 ADC Therapy

Zai Lab Limited announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd.  to use MediLi...

January 13, 2025 | Monday | News
Timberlyne Therapeutics Secures $180 Million in Series A Financing to Advance CM313 for Autoimmune Diseases

Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders, announced the c...

January 10, 2025 | Friday | News
Primo Biotechnology Partners with SHINE Technologies to Distribute Ilumira® in Asia-Pacific

Primo Biotechnology (“Primo”) announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear ...

January 09, 2025 | Thursday | News
Merck's GARDASIL® Becomes First HPV Vaccine Approved for Males in China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the National Medical Products Administration (NMPA) of China approv...

January 09, 2025 | Thursday | News
Jacobio Pharma's KRAS G12C Inhibitor Glecirasib Data Published in Nature Medicine, Showcasing Impressive Efficacy in NSCLC

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced that the data from a registrational clinical trial of...

January 07, 2025 | Tuesday | News
Astellas’ VYLOY™ (Zolbetuximab) Approved in China for First-Line Treatment of Advanced Gastric and GEJ Cancer

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that China's National Medical Products Administ...

January 06, 2025 | Monday | News
GSK's Nucala (Mepolizumab) Approved in China for Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

GSK plc (LSE/NYSE: GSK) announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibod...

January 06, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close